Global Schizophrenia Treatment Market
Schizophrenia is a mental condition that disrupts the brain function. Schizophrenia patients may experience psychosis, which can lead to difficulties with clarity of thought, emotions, and understanding reality. 
This can lead to hallucinations (hearing or seeing things) and delusions (false beliefs). 
Psychosis can lead to a desire to avoid social situations. Individuals may struggle to understand others' emotions, leading to feelings of depression or irritability. 
Similar disorders to schizophrenia include schizoaffective disorder and schizophreniform disorder. 
Many community members lack understanding about schizophrenia. Individuals with schizophrenia and their families may experience additional distress due to the attitudes and behaviors of others.
 

Types Of Schizophrenia

• Paranoid schizophrenia
• Hebephrenic schizophrenia
• Catatonic schizophrenia
• Undifferentiated schizophrenia
• Residual schizophrenia
• Simple schizophrenia
• Cenesthopathic schizophrenia
• Unspecified schizophrenia
   

Symptoms

• Hallucinations
• Delusions
• Unusual thinking and speech
• Having problems thinking clearly
• Not being able to make decisions and having trouble making plans
• Having trouble interpreting other people’s emotions and motives
• Suicidal thoughts
   

Market Dynamics

Drivers:

• Rising prevalence of schizophrenia globally.
• Increasing awareness and early diagnosis of the disorder.
• Advancements in pharmaceutical and therapeutic treatments.
• Growing investment in mental health infrastructure and services.
• Recreational drug use: Schizophrenia is associated with the use of some recreational substances, particularly in bigger quantities and earlier in life.

Restraints:

• High cost of treatment and medication. As with other schizophrenia medications, these second-generation anti-psychotic drugs vary widely in cost but can be quite expensive. 
• Side effects associated with antipsychotic medications: Relatively minor tolerability issues (e.g., mild sedation or dry mouth) to very unpleasant (e.g., constipation, akathisia, sexual dysfunction) to painful (e.g., acute dystonias) to disfiguring (e.g., weight gain, tardive dyskinesia) to life threatening (e.g., myocarditis, agranulocytosis). 
• Stigma surrounding mental health disorders.
• Restraint was usually described as a pragmatic action, seen as a strategy to manage the illness, based on protecting the person with schizophrenia or the wider community, or was felt to be necessary in order to access treatment.

Challenges:

• Limited access to mental health services in developing regions.
• High dropout rates in clinical trials for new medications. Demonstrating the efficacy of candidate drugs to treat schizophrenia can be especially challenging: developers must contend with high patient dropout in clinical trials for this disease, treatment effects are often modest, placebo response has been increasing in recent years.
• Compliance issues with long-term medication use. Medication nonadherence is common in patients with schizophrenia. Nonadherence affects approximately half of all patients and may increase the risk of relapse and hospitalization. Although it is an intensively studied phenomenon, we have little understanding of underlying mechanisms leading to nonadherence.
   

Opportunities:

• Development of novel therapeutic options, including digital therapeutics.
• Increasing focus on personalized medicine and genomics: The push for personalized medicine highlights the need for treatment modalities tailored to individuals' genetic, biomarker, and psychosocial characteristics. Genome-wide association studies reveal schizophrenia as a polygenic disorder, indicating varied genetic profiles among patients.
• Expansion of telemedicine and online therapy services: to assess the types and nature of distant interventions for patients with schizophrenia, either telephone-based, internet-based or video-based telehealth systems.

Causes Of Schizophrenia

• Imbalances in the chemical signals that your brain uses to communicate with other cells. 
• Brain development issues before birth. 
• Loss of connections between different parts of the brain.

Market Segmentations:

• By Treatment Type:

Antipsychotic Medications

• By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies.

Schizophrenia Medication:

• First-generation antipsychotics 
  Haloperidol
  Fluphenazine
  Chlorpromazine
  Perphenazine

• Second-generation antipsychotics Aripiprazole.
  Asenapine 
  Brexpiprazole
  Cariprazine 
  Clozapine 
  Iloperidone 
  Lumateperone
  Lurasidone 
  Olanzapine 
  Paliperidone
  Quetiapine 
  Risperidone

• Long-acting injectable antipsychotics Aripiprazole.
  Fluphenazine decanoate
  Haloperidol decanoate
  Paliperidone 
  Risperidone
  Ziprasidone
   

Major Companies

Johnson & Johnson

Eli Lilly and Company

AbbVie Inc.(Allergan Plc)

Alkermes PLC
Otsuka Pharmaceutical
Avineuro Pharmaceuticals
Boehringer Ingelheim
GW Research
Karuna Pharmaceuticals
Newron Pharmaceuticals
Acadia Pharmaceuticals
Rovi Pharmaceuticals Laboratories
Minerva Neurosciences

BioXcel Therapeutics
 

Market Segmentation in Proper Form

By Treatment Type:

• Antipsychotic Medications
• First-Generation
• Second-Generation
• Long-Acting Injectables

By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Latest News & Recent Development News

• In February 2022,Vanderbilt University has signed an exclusive, worldwide license and a research collaboration agreement with Neumora Therapeutics to develop and commercialize M4-selective muscarinic receptor positive allosteric modulator program for schizophrenia and other neuropsychiatric disorders.

• In 11 March 2022, AbbVie (NYSE: ABBV) and Gedeon Richter Plc. ('Richter') today announced a new co-development and license agreement to research, develop and commercialize novel dopamine receptor modulators for the potential treatment of neuropsychiatric diseases.